First portable, AI-powered diabetic retinopathy screening solution for on-the-spot diagnosis

Digital health startup AEYE Health, the leader in artificial intelligence (AI)-based diagnostics for retinal imaging in the US, and Finland-based Optomed, a leader in portable retinal devices, have unveiled Aurora AEYE, the first-ever portable, fully autonomous screening diabetic retinopathy screening solution.

Aurora AEYE enables screening patients anywhere-whether at-home or in clinics- providing instant diagnostic results without the need for  human interpretation.

The launch of Aurora AEYE will take place at the American Diabetes Association's 84th Scientific Session in Orlando, from June 21-24. 

Aurora AEYE is the first US FDA-cleared solution of its kind, requires just one image per eye and provides instant results directly on the camera screen for patients, along with diagnostic reports for healthcare providers. Its portable internet-connected design allows screenings in clinics, patients bedsides, and homes. Aurora AEYE promises to revolutionise diabetic retinopathy screening, by enhancing accessibility and efficiency, ultimately improving patient outcomes and promoting global health equity.

The solution streamlines insurance reporting and care gap closure with automatically generated diagnostic reports. Reimbursement is facilitated by a dedicated AI CPT code 92229 for autonomous screening, significantly enhancing accessibility. Additionally, it serves as a crucial HEDIS measure and contributed to star ratings for most health plans.